Search results for "Cholesterol"

showing 10 items of 1211 documents

Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE-/- mice.

2018

Background The endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) is a known modulator of inflammation and ligand to both, pro-inflammatory cannabinoid receptor 1 (CB1) and anti-inflammatory CB2. While the role of both receptors in atherogenesis has been studied extensively, the significance of 2-AG for atherogenesis is less well characterized. Methods The impact of 2-AG on atherogenesis was studied in two treatment groups of ApoE-/- mice. One group received the monoacylglycerol lipase (MAGL)-inhibitor JZL184 [5 mg/kg i.p.], which impairs 2-AG degradation and thus causes elevated 2-AG levels, the other group received vehicle for four weeks. Simultaneously, both groups were fed a high-chole…

Male0301 basic medicineCCR1Chemokinelcsh:MedicineSmooth Muscle Cells030204 cardiovascular system & hematologyPathology and Laboratory MedicineBiochemistryMonocytesWhite Blood CellsMicechemistry.chemical_compoundChemokine receptorSpectrum Analysis Techniques0302 clinical medicinePiperidinesAnimal CellsCell MovementMedicine and Health SciencesReceptorlcsh:ScienceImmune ResponseJZL184MultidisciplinarybiologyNeurochemistryFlow CytometryLipidsCholesterolSpectrophotometryCytophotometryCellular TypesNeurochemicalsAnatomymedicine.symptomResearch Articlemedicine.medical_specialtyImmune CellsImmunologyMuscle TissueAntigens Differentiation MyelomonocyticInflammationArachidonic AcidsResearch and Analysis MethodsDiet High-FatCell LineGlycerides03 medical and health sciencesSigns and SymptomsApolipoproteins EDiagnostic MedicineAntigens CDInternal medicinemedicineAnimalsOil Red OBenzodioxolesInflammationMuscle CellsBlood CellsMacrophageslcsh:RBiology and Life SciencesCell BiologyAtherosclerosisMonoacylglycerol lipaseBiological Tissue030104 developmental biologyEndocrinologychemistrybiology.proteinlcsh:QEndocannabinoidsNeurosciencePLoS ONE
researchProduct

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

2016

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be…

Male0301 basic medicineCell signalingHIPERCOLESTEROLEMIALow-density lipoprotein receptor gene familyHypercholesterolemiaMice TransgenicFamilial hypercholesterolemiaBiologyAntiviral AgentsPermeabilityMice03 medical and health sciencesAlzheimer DiseasemedicineAnimalsHomeostasisHumansGlucose homeostasisRNA Small InterferingEpithelial Sodium ChannelsGlycoproteinsNeuronsPCSK9PCSK9 InhibitorsAntibodies MonoclonalCell DifferentiationOligonucleotides Antisensemedicine.diseaseProprotein convertaseLipidsCircadian RhythmLiver RegenerationCell biology030104 developmental biologyReceptors LDLBiochemistryLDL receptorKexinFemalelipids (amino acids peptides and proteins)CRISPR-Cas SystemsProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hy…

2018

International audience; Background and Aim: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Our aim was to evaluate the differences in Lp-PLA2 activity in a population of hypercholesterolemic patients with and without definite FH.Methods and Results: Hypercholesterolemic patients were consecutively recruited. Definite FH was defined according to Dutch Lipid Clinic Netwo…

Male0301 basic medicineEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Low density lipoproteinDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compound0302 clinical medicineVascular inflammationeducation.field_of_studyNutrition and Dieteticsmedicine.diagnostic_testGenetic disorderMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseLipidsUp-Regulation3. Good healthPhenotypeLow-density lipoproteinApolipoprotein B-100Femalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyStatin treatmentHypercholesterolemiaFamilial hypercholesterolemiaPopulationPhysical examinationHyperlipoproteinemia Type II03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansLipoprotein-associated phospholipase A2Plaque vulnerabilityeducationAgedApolipoprotein A-Ibusiness.industryCholesterol HDLCholesterol LDLStatin treatmentAtherosclerosisCardiovascular riskmedicine.diseaseCross-Sectional Studies030104 developmental biologychemistry1-Alkyl-2-acetylglycerophosphocholine EsteraseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersLipoproteinNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients

2016

IF 3.942; International audience; Background and aims: Diabetic patients are at high risk of stroke and coronary artery disease. Recent data suggest that arachidonic acid metabolism is altered in diabetic conditions and that these alterations contribute to accelerated atherosclerosis. Little is known about how these alterations affect the metabolism and the proportions of different lipid species within the atherosclerotic plaque. The aim of our study was to perform a targeted lipidomic analysis of human atherosclerotic lesions, with a specific focus on PUFA-containing lipid species, to reveal differences in the fatty-acid composition of plaque in diabetic patients compared with non-diabetic…

Male0301 basic medicineEndothelial lipasePathologymedicine.medical_treatmentCoronary Artery DiseaseCarotid endarterectomy030204 cardiovascular system & hematologyCohort StudiesCoronary artery diseasechemistry.chemical_compound0302 clinical medicineEndarterectomy CarotidLysophosphatidylcholineDiabetesMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosisLipidsPlaque Atherosclerotic3. Good healthStrokeCholesterolArachidonic acidCholesteryl esterFemalelipids (amino acids peptides and proteins)Arachidonic acidCardiology and Cardiovascular Medicinemedicine.medical_specialtyContext (language use)Biology03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiabetes mellitusInternal medicinemedicineHumansAgedLysophosphatidylcholinesLipaseAtherosclerosismedicine.disease030104 developmental biologyAtheromaEndocrinologyDiabetes Mellitus Type 2chemistryMultivariate AnalysisEicosanoidsAtherosclerosis
researchProduct

Anti-obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zücker fatty rats

2018

We evaluated the effect of oral administration of Bifidobacterium animalis subsp. lactis CECT 8145 strain in Zücker fatty rats. The Zücker fatty rats were randomly divided into two groups (n=10 each) and administered either B. animalis subsp. lactis CECT 8145 (1010 cfu/day) suspended in skim milk, or skim milk alone (control group). Each treatment was administered in drinking bottles from week 5 until week 17 of age. A lean Zücker rat group (standard group) was included to provide normal values for the Zücker strain. This group was administered skim milk in the drinking bottle for the same experimental period as Zücker fatty rats. Body weight gain was greater in the fatty control group tha…

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtyfood.ingredient030209 endocrinology & metabolismCarbohydrate metabolismWeight GainMicrobiologyEating03 medical and health scienceschemistry.chemical_compound0302 clinical medicinefoodBifidobacterium animalisOral administrationMalondialdehydeInternal medicineAppetite DepressantsSkimmed milkmedicineAnimalsHumansObesityTriglyceridebiologyTumor Necrosis Factor-alphaChemistryCholesterolProbioticsLipid MetabolismMalondialdehydebiology.organism_classificationGhrelinRatsRats ZuckerBifidobacterium animalisDisease Models AnimalGlucose030104 developmental biologyEndocrinologymedicine.symptomWeight gainBeneficial Microbes
researchProduct

Muricholic Acids Promote Resistance to Hypercholesterolemia in Cholesterol-Fed Mice

2021

International audience; Background and aims: Hypercholesterolemia is a major risk factor for atherosclerosis and cardiovascular diseases. Although resistant to hypercholesterolemia, the mouse is a prominent model in cardiovascular research. To assess the contribution of bile acids to this protective phenotype, we explored the impact of a 2-week-long dietary cholesterol overload on cholesterol and bile acid metabolism in mice. Methods: Bile acid, oxysterol, and cholesterol metabolism and transport were assessed by quantitative real-time PCR, western blotting, GC-MS/MS, or enzymatic assays in the liver, the gut, the kidney, as well as in the feces, the blood, and the urine. Results: Plasma tr…

Male0301 basic medicineMuricholic acidDrug Evaluation PreclinicalReceptors Cytoplasmic and NuclearCholesterol Dietarychemistry.chemical_compound0302 clinical medicineBiology (General)Spectroscopy2. Zero hungerKidney[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyBile acidChemistryGeneral Medicine3. Good healthComputer Science ApplicationsBlotChemistrymedicine.anatomical_structureCholesterolFXR030220 oncology & carcinogenesislipids (amino acids peptides and proteins)LXRmedicine.medical_specialtyOxysterolQH301-705.5medicine.drug_classHypercholesterolemiaArticleCatalysisBile Acids and SaltsInorganic Chemistry03 medical and health sciencesIn vivoInternal medicinemedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPhysical and Theoretical ChemistryLiver X receptorQD1-999Molecular BiologyCholesterolOrganic ChemistryCholic AcidsBile acidsMice Inbred C57BL030104 developmental biologyEndocrinology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Homozygous Familial Hypercholesterolemia in Spain Prevalence and Phenotype-Genotype Relationship

2016

Background— Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease. HoFH is caused by mutations in several genes, including LDL receptor ( LDLR ), apolipoprotein B ( APOB ), proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), and LDL protein receptor adaptor 1 ( LDLRAP1 ). No epidemiological studies have assessed HoFH prevalence or the clinical and molecular characteristics of this condition. Here, we aimed to characterize HoFH in Spain. Methods and Results— Data were collected from the Spanish Dyslipidemia Regist…

Male0301 basic medicineOncologyLdl receptor geneApolipoprotein BLipid-lowering therapyFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity0302 clinical medicineAutosomal-dominant hypercholesterolemiaRisk FactorsEpidemiologyPrevalenceDiseaseRegistriesGenetics (clinical)Molecular EpidemiologybiologyhypercholesterolemiaHomozygoteDouble-blindMiddle AgedPhenotypeCardiovascular DiseasesApolipoprotein B-100allelesFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineMutationsAdultGenetic MarkersHeterozygotemedicine.medical_specialtyInhibitorAdolescentPlacebo-controlled trialHyperlipoproteinemia Type IIlipidsYoung Adult03 medical and health sciencesInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleAdaptor Proteins Signal TransducingRecessive hypercholesterolemiaPCSK9registriesCholesterol LDLApolipoprotein-bmedicine.disease030104 developmental biologyEndocrinologyReceptors LDLSpainMutationLDL receptorbiology.proteinmutationDyslipidemia
researchProduct

CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice

2018

Abstract Aims CD40 ligand (CD40L) signaling controls vascular oxidative stress and related dysfunction in angiotensin-II-induced arterial hypertension by regulating vascular immune cell recruitment and platelet activation. Here we investigated the role of CD40L in experimental hyperlipidemia. Methods and results Male wild type and CD40L−/− mice (C57BL/6 background) were subjected to high fat diet for sixteen weeks. Weight, cholesterol, HDL, and LDL levels, endothelial function (isometric tension recording), oxidative stress (NADPH oxidase expression, dihydroethidium fluorescence) and inflammatory parameters (inducible nitric oxide synthase, interleukin-6 expression) were assessed. CD40L exp…

Male0301 basic medicinePhysiologyAnti-Inflammatory AgentsNitric Oxide Synthase Type II030204 cardiovascular system & hematologyWeight Gainmedicine.disease_causeAntioxidantschemistry.chemical_compound0302 clinical medicineHyperlipidemiaEndothelial dysfunctionMice KnockoutbiologyLeptinLipidsVasodilationNitric oxide synthaseInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular Medicinemedicine.medical_specialtyCD40 LigandHyperlipidemiasInflammationDiet High-Fat03 medical and health sciencesPhysiology (medical)Internal medicinemedicineAnimalsHumansObesityPlatelet activationInflammationTNF Receptor-Associated Factor 6Interleukin-6Cholesterolbusiness.industryMyocardiumNADPH OxidasesPlatelet Activationmedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinEndothelium VascularbusinessBiomarkersOxidative stressCardiovascular Research
researchProduct

Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study

2017

Background: The role of polyphenol intake on cardiovascular risk factors is little explored, particularly in people with diabetes. Aim: To evaluate the association between the intake of total polyphenols and polyphenol classes with the major cardiovascular risk factors in a population with type 2 diabetes. Methods: Dietary habits were investigated in 2573 males and females participants of the TOSCA.IT study. The European Prospective Investigation on Cancer and Nutrition (EPIC) questionnaire was used to assess dietary habits. In all participants, among others, we assessed anthropometry, plasma lipids, blood pressure, C-reactive protein and HbA1c following a standard protocol. The USDA and Ph…

Male0301 basic medicinePhysiologyType 2 diabetes030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineDietary polyphenolsFlavonoidsPhenolic acidsCardiovascular riskType 2 diabetesLOW-GRADE INFLAMMATIONBLOOD-PRESSUREDIETARY POLYPHENOLSDARK CHOCOLATEINSULIN SENSITIVITYRANDOMIZED-TRIALSDISEASEMETAANALYSISMETABOLISMCHOLESTEROLRisk FactorsSurveys and QuestionnairesHydroxybenzoatesProspective StudiesFood scienceCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabeteseducation.field_of_studyPhenolic acidNutrition and Dieteticsbiologyfood and beveragesType 2 diabetesDietary polyphenolMiddle AgedDietary polyphenols; Flavonoids; Phenolic acids; Cardiovascular risk; Type 2 diabetesEuropean Prospective Investigation into Cancer and NutritionDietary polyphenolsCardiovascular DiseasesFemalePhenolic acidsPopulationCardiovascular risk Dietary polyphenols Flavonoids Phenolic acids Type 2 diabetes03 medical and health sciencesDiabetes mellitusmedicineHumanseducationTriglyceridesAgedFlavonoids030109 nutrition & dieteticsDose-Response Relationship Drugbusiness.industryCholesterol HDLC-reactive proteinPolyphenolsCholesterol LDLAnthropometrymedicine.diseaseCardiovascular riskCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabetes; Nutrition and Dietetics; Critical Care and Intensive Care MedicineDietCross-Sectional StudiesNutrition AssessmentDiabetes Mellitus Type 2chemistryFlavonoidbiology.proteinGlycated hemoglobinbusinessBody mass index
researchProduct

Lipidomic profiling identifies signatures of metabolic risk

2020

Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. Results: Thirty-nine lipids were…

Male0301 basic medicineResearch paperdhSL dihydrosphingolipidBMI body mass indexlcsh:MedicineATHEROGENIC LIPOPROTEINSBioinformaticsFHS Framingham Heart StudyPC phosphatidylcholinePESA Progression of Early Subclinical Atherosclerosis0302 clinical medicineFramingham Heart StudyRisk FactorsSAFHS San Antonio Family Heart StudyLC-MS/MS liquid chromatography-tandem mass spectrometryMedicineLongitudinal StudiesMetabolic riskPLASMA SPHINGOLIPID METABOLISMPOPULATIONlcsh:R5-920education.field_of_studySPHINGOMYELINCE cholesteryl esterDysglycemiaGeneral MedicineMiddle AgedLipidomePS phosphatidylserineCardiovascular diseaseLipidsMetabolic syndrome3. Good healthCARDIOVASCULAR-DISEASE030220 oncology & carcinogenesisHEARTMetS metabolic syndromeFemaleDisease SusceptibilityLGPL lysoglycerophospholipidSL sphingolipidlcsh:Medicine (General)LPE lysophosphatidylethanolamineAdultFDR false discovery rateTAG triacylglycerolPopulationCer ceramideCVD cardiovascular diseasePE phosphatidylethanolamineDENSITY-LIPOPROTEINRisk AssessmentGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsHumanseducationT2DM type II diabetes mellitusAgedLPC lysophosphatidylcholineSM sphingomyelinbusiness.industryCERAMIDElcsh:RHDL-C High density lipoprotein cholesterolBiomarkerLipid Metabolismmedicine.diseaseObesitySphingolipidCross-Sectional Studies030104 developmental biologyDyslipidemiaERF Erasmus Family StudyLipidomicsMetabolic syndromeINDUCED INSULIN-RESISTANCEbusinessDAG diacylglycerolBody mass indexBiomarkersDyslipidemiaMRM multiple reaction monitoringFASTING GLUCOSE
researchProduct